The Precision Peptide Company Inc. PNGAF
0.21 USD -0.01 (-2.64%)
At closeNov 4, 2026, 4:00 PM EST
0.19 Day range 0.1981
0.0077 52-week range 0.4099
- YTD
- +1.74%
- 1 year
- -20.06%
- Market cap
- 11.68M
- EPS (ttm)
- -0.15
- YTD return
- +1.74%
- 1-year return
- -20.06%
- Volume
- 74.06K
- Avg volume
- 38.09K
- Open
- 0.1981
- Previous close
- 0.2157
- Day's range
- 0.19 – 0.1981
- 52-week range
- 0.0077 – 0.4099
5D -0.0500 (-20.83%)
News
The Precision Peptide Company Moves Early on New Federal Peptide Policy, Adding All Six Covered Peptides to Its Prescription Platform 
The Precision Peptide Company's Needle-Free First Strategy Already in Place as HHS Draft Policy Recognizes Non-Injectable Routes for Leading Peptides 
The Precision Peptide Company Quadruples U.S. Telehealth Formulary to 16 Prescription Therapies Across Seven Therapy Areas 
The Precision Peptide Company Highlights 30 Years of Peptide Science Behind Its Product Platform 
The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line 
The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing 
RETRANSMISSION: The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch 
The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch 
The Precision Peptide Company Expands U.S. Wholesale Program, Opening Distribution of Its Needle-Free Range to Clinics, Med Spas, Gyms and Retailers 
The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event
Your note
Sign in to keep a note on PNGAF — it syncs with the Stock Master app.